Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease

Leukemia Research

Volumn 35, Issue 3, 2011, Pages 363-368

  D'Arena, Giovanni ^a   Laurenti, Luca ^b   Minervini, Maria Marta ^a   Deaglio, Silvia ^c   Bonello, Lisa ^c   De Martino, Laura ^d   De Padua, Laura ^b   Savino, Lucia ^a   Tarnani, Michela ^b   De Feo, Vincenzo ^d   Cascavilla, Nicola ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF SALERNO   (Italy)

Author keywords

Autoimmunity; CD127; Chronic lymphocytic leukemia; Disregulation; Flow cytometry; Immune system; Regulatory T cells

Indexed keywords

CD38 ANTIGEN; LACTATE DEHYDROGENASE; PROTEIN KINASE ZAP 70;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER GROWTH; CANCER STAGING; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOGLOBULIN VARIABLE REGION; LYMPHOCYTE COUNT; LYMPHOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD38; B-LYMPHOCYTES; CASE-CONTROL STUDIES; CHROMOSOME ABERRATIONS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; SURVIVAL RATE; T-LYMPHOCYTES, REGULATORY; TUMOR MARKERS, BIOLOGICAL; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 79952100710     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.08.010     Document Type: Article

References (28)

1. Chiorazzi N., Rai K.R., Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005, 352:804-815.
2. Hamblin A.D., Hamblin T.J. The immunodeficiency of chronic lymphocytic leukaemia. Br Med Bull 2008, 87:49-52.
3. Sakaguchi S., Wing K., Miyara M. Regulatory T cells - a brief history and perspective. EurJ Immunol 2007, 37:S116-123.
4. Beyer M., Kochanek M., Darabi K., Popov A., et al. Reduced frequencies and suppressive function of CD4+CD25 high regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005, 106:2018-2025.
5. Giannopoulos K., Schmitt M., Kowal M., Wlasiuk P., et al. Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep 2008, 20:677-682.
6. Giannopoulos K., Schmitt M., Wlasiuk P., Chen J., et al. The high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide. Leukemia 2008, 22:222-224.
7. Deutsch V., Perry C., Polliack A. Expansion of regulatory T cells in B chronic lymphocytic leukemia: enhanced 'brakes' on host immunity. Leuk Lymphoma 2009, 50:687-688.
8. Jak M., Mous R., Remmerswaal E.B.M., Spijker R., et al. Enhanced formation and survival of CD4+CD25hiFoxp3+ T-cells in chronic lymphocytic leukemia. Leuk Lymphoma 2009, 50:788-801.
9. Beyer M., Schultze J.L. Regulatory T cells in cancer. Blood 2006, 108:804-811.
10. Baecher-Allan C., Hafler D.A. Human regulatory T cells and their role in autoimmune disease. Immunol Rev 2006, 212:203-216.
11. Baecher-Allan C., Brown J.A., Freeman G.J., Hafler D.A. CD4+CD25 high regulatory cells in human peripheral blood. J Immunol 2001, 167:1245-1253.
12. Liu W., Putnam A.L., Xu-yu Z., Szot G.L., et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ Treg cells. J Exp Med 2006, 203:1701-1711.
13. Seddiki N., Santner-Nanan B., Martinson J., Zaunders J., et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006, 203:1693-1700.
14. Hallek M., Cheson B.D., Catovsky D., Caligaris-Cappio F., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National cancer Institute - Working Group 1996 guidelines. Blood 2008, 11:5446-5456.
15. Battaglia M., Roncarolo M.G. The fate of human Treg cells. Immunity 2009, 30:763-765.
16. Chatila T.A. Role of regulatory T cells in human diseases. J Allergy Clin Immunol 2005, 116:949-1949.
17. Sakaguchi S., Wing K., Miyara M. Regulatory T cells - a brief history and perspective. Eur J Immunol 2007, 37:S116-123.
18. Sakaguchi S., Wing K., Onishi Y., Prieto-M P., et al. Regulatory T cells: how do they suppress immune responses?. Int Immunol 2009, 21:1105-1111.
19. Deaglio S., Vaisitti T., Aydin S., Ferrero E., et al. In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. Blood 2006, 108:1135-1144.
20. Damle R.N., Tamburni S., Calissano C., Yancopoulos S., et al. CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood 2007, 110:3352-3359.
21. Calissano C., Damle R.N., Heyes G., Murphy E.J., et al. In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia. Blood 2009, 114:4832-4842.
22. Deaglio S., Malavasi F. Chronic lymphocytic leukemia microenvironment: shifting the balance from apoptosis to proliferation. Haematologica 2009, 94:752-756.
23. Stasi R., Cooper N., Del Poeta G., Stipa E., et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B-cell depleting therapy with rituximab. Blood 2008, 112:1147-1150.
24. Colombo M.P., Piconese S. Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer 2007, 7:880-887.
25. Corthay A. How do regulatory T cells work?. Scand J Immunol 2009, 70:326-336.
26. Robak T. Improving FCR immunochemotherapy in CLL. Blood 2010, 115:437-438.
27. Byrd J.C., Kipps T.J., Flinn I.W., Castro J., et al. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed chronic lymphocytic leukemia. Blood 2010, 115:489-495.
28. Rech A.J., Vonderheide R.H. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T-cells. Ann N Y Acad Sci 2009, 1174:99-106.